2
Announcements
Trials
Browse
Landscape
Status
Recruiting
2
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
82
Observational
4
Sponsor
Cancer Type
Dermatologic
3
Gastrointestinal
1
Conditions
Melanoma
3
Colorectal Neoplasms
1
Interventions
Surveys and Questionnaires
543
Blood Specimen Collection
446
Surgical Procedures, Operative
164
Observation
152
Drug Therapy
142
Radiotherapy
141
Interviews as Topic
139
Gene Expression Profiling
129
Biopsy
117
Magnetic Resonance Spectroscopy
116
Immunohistochemistry
112
Data Collection
95
Polymerase Chain Reaction
87
Specimen Handling
81
Amplified Fragment Length Polymorphism Analysis
81
Bevacizumab
78
Microarray Analysis
76
Flow Cytometry
69
Neoadjuvant Therapy
68
Watchful Waiting
66
Magnetic Resonance Imaging
65
Immune Checkpoint Inhibitors
61
Nivolumab
60
Immunotherapy
57
Therapeutics
55
Reverse Transcriptase Polymerase Chain Reaction
52
pembrolizumab
50
Ultrasonography
47
Positron Emission Tomography Computed Tomography
47
Hematologic Tests
46
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Observational
×
encorafenib
×
Clear all
NCT07022457
2026-04-13
UK-EnBiRiM
Pierre Fabre Ltd
Active not recruiting
50 enrolled
NCT05260684
2025-03-06
OCEANMIST
Pfizer
Completed
716 enrolled
10 charts
NCT04673955
2022-09-29
BERING-CRC
Pierre Fabre Pharma GmbH
Recruiting
500 enrolled
NCT04045691
2021-01-19
BERING
Pierre Fabre Pharma GmbH
Recruiting
750 enrolled